Literature DB >> 2521474

Different immune mechanisms leading to autoimmunity in primary sclerosing cholangitis and autoimmune chronic active hepatitis of childhood.

G Mieli-Vergani1, A Lobo-Yeo, B M McFarlane, I G McFarlane, A P Mowat, D Vergani.   

Abstract

Children with primary sclerosing cholangitis or autoimmune chronic active hepatitis have similar high levels of immunoglobulin G and non-organ-specific autoantibodies and may have similar histological features. To investigate a possible immunopathogenesis of primary sclerosing cholangitis, we have studied a series of regulatory and/or effector immune mechanisms in eight children with primary sclerosing cholangitis, comparing them to 14 children with autoimmune chronic active hepatitis and 24 healthy children as controls. Antibodies to a liver membrane protein preparation were found in all children with autoimmune chronic active hepatitis tested and in seven of eight with primary sclerosing cholangitis, whereas antibodies against the hepatic asialoglycoprotein receptor were present in three of six patients with autoimmune chronic active hepatitis and in two of the eight with primary sclerosing cholangitis. Lymphocyte cytotoxicity values to autologous hepatocytes were similarly elevated in primary sclerosing cholangitis (median: 50%; range: 38 to 83%) and in autoimmune chronic active hepatitis (median: 52%; range 37 to 87%) compared to controls (median: 8%; range: 0 to 27%) (p less than 0.01 for both). In contrast, T suppressor cell number and function were normal in patients with primary sclerosing cholangitis (median: 23%; range: 19 to 28%; and median: 54%; range: 44 to 61%), but significantly decreased in patients with autoimmune chronic active hepatitis (median: 15%; range: 9 to 21%; and median: 9%; range: -40 to +21%) when compared to controls (median: 24%; range: 16 to 29%; and median: 53%; range: 8 to 77%) (p less than 0.01 for both).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2521474     DOI: 10.1002/hep.1840090206

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  13 in total

Review 1.  Autoimmune hepatitis.

Authors:  E A Roberts
Journal:  Indian J Pediatr       Date:  1995 Sep-Oct       Impact factor: 1.967

Review 2.  Primary sclerosing cholangitis.

Authors:  S A Mitchell; R W Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

Review 3.  Immunological abnormalities and hepatotropic viral infections.

Authors:  I G McFarlane
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

4.  Suppressor T-cell deficiency in primary sclerosing cholangitis. Case and family study.

Authors:  A E Kilby; E L Krawitt; R J Albertini; B F Chastenay; A John
Journal:  Dig Dis Sci       Date:  1991-09       Impact factor: 3.199

Review 5.  Liver disease in infancy: a 20 year perspective.

Authors:  G Mieli-Vergani; E R Howard; A P Mowat
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

Review 6.  The immunology of primary sclerosing cholangitis.

Authors:  R W Chapman
Journal:  Springer Semin Immunopathol       Date:  1990

Review 7.  Aetiology and pathophysiology of chronic liver disorders.

Authors:  J Schölmerich; A Holstege
Journal:  Drugs       Date:  1990       Impact factor: 9.546

8.  Antineutrophil antibody: a test for autoimmune primary sclerosing cholangitis in childhood?

Authors:  S K Lo; R W Chapman; P Cheeseman; C P Charlton; J A Walker-Smith; G Mieli-Vergani; K A Fleming
Journal:  Gut       Date:  1993-02       Impact factor: 23.059

9.  Asymptomatic autoimmune chronic active hepatitis in a male adolescent.

Authors:  S Peeters; U Blecker; J De Valck; A Goossens; M Hautekeete; G Devis; Y Vandenplas
Journal:  Eur J Pediatr       Date:  1993-02       Impact factor: 3.183

10.  Significance of extractable nuclear antigens in childhood autoimmune liver disease.

Authors:  G V Gregorio; E T Davies; G Mieli-Vergani; D Vergani
Journal:  Clin Exp Immunol       Date:  1995-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.